ClinicalTrials.gg

Program

ALG-055009

A development code.

Its studies are mostly in Non-alcoholic Fatty Liver Disease, led by Aligos Therapeutics.

Furthest: phase 2, since Mar 15, 20244 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aligos Therapeutics40 open or runningphase 2since Mar 15, 2024Oct 11, 2021none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 11, 2021First study: phase 1 study in Non-alcoholic Fatty Liver DiseaseFirst studyNCT05090111 · 98 enrolled · France
  2. Nov 3, 2023Phase 1 study in Healthy VolunteersNCT06191991 · 14 enrolled · United States
  3. Mar 15, 2024Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT06342947 · 102 enrolled · United States
  4. Mar 24, 2025Phase 1 study in Healthy Volunteer StudyNCT06959888 · 8 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06959888Healthy Volunteer Study · United States1CompletedMay 8, 20258
NCT06342947Non-alcoholic Fatty Liver Disease · United States2CompletedAug 19, 2024102
NCT06191991Healthy Volunteers · United States1CompletedNov 27, 202314
NCT05090111Non-alcoholic Fatty Liver Disease · France1CompletedJun 16, 202398

How it is read

Names in the registry

  • “ALG-055009”, 4 entries

Codes read as this program: ALG055009.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.